Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) has announced the appointment of Roger McIntyre as its new chief executive.
McIntyre is professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.
He is also executive director of the Brain and Cognition Discovery Foundation in Toronto; director and chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance in Chicago; professor and Nanshan scholar at Guangzhou Medical University; and adjunct professor at the College of Medicine at Korea University.
READ: Champignon Brands appoints MediPharm Labs CEO Pat McCutcheon to board of directors
The new CEO is also a clinical professor at the State University of New York Upstate Medical University, Syracuse, New York, and a clinical professor, Department of Psychiatry and Neurosciences, at the University of California Riverside School of Medicine.
Prior to joining Champignon, McIntyre implemented and developed the Canadian Rapid Treatment Centre of Excellence (CRTCE), the country's first-ever rapid-onset treatment centre for persons with mood disorders.
The CRTCE is the only centre in North America and globally to demonstrate that rapid-onset treatments improve health outcomes in one to two weeks and get people back to work, which is of enormous importance to individuals, as well as payers in the private space, the company said.
McIntyre is replacing outgoing CEO Gareth Birdsall, who will relinquish his position but maintain his directorship of Champignon.
The company also said it is contemplating a name change to ”better reflect its diverse business lines and operating subsidiaries”.
In a statement, Birdsall said: “We are extremely pleased and fortunate to be able to bring Dr McIntyre aboard as CEO. Dr McIntyre’s is the world’s leading authority on depression and associated mood disorders, which is further crystallized by his foresight in founding Canada’s first integrated mood disorder treatment and integrated research center in the CRTCE.
"Dr McIntyre’s clear ability to execute and his entrepreneurial nature, along with a demonstrated capacity to lead and delegate in dynamic and growing organizations, represent the skill sets that Champignon needs as it moves towards our North American clinic expansion and maturing novel drug discovery initiatives.”
Champignon is focused on the formulation and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery platforms for nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform.
Contact the author of this article at calum@proactiveinvestors.com
Follow him on Twitter at @Cal_Proac